Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Giralt

Showing results (141-150 of 176) with videos related to

Pageof 18
Sort By:
Blood|November 24, 2001
The effect of pretransplant interferon therapy on the outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phaseS J Lee, J P Klein, C Anasetti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 15, 2008
High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients >65 years of ageC Hosing, R M Saliba, G-J Okoroji, et al.
Blood|December 1, 1996
Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantationD Przepiorka, C Ippoliti, I Khouri, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 1, 1997
Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patientsK van Besien, P Thall, M Korbling, et al.
Bone Marrow Transplantation|May 21, 2008
Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric populationJ E Levine, A J Barrett, M-J Zhang, et al.
Blood|December 1, 1995
CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantationS Giralt, J Hester, Y Huh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1997
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantationR H Collins, O Shpilberg, W R Drobyski, et al.
Bone Marrow Transplantation|October 12, 1999
Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantationD Przepiorka, I Khouri, C Ippoliti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 23, 1999
Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphomaD Przepiorka, K van Besien, I Khouri, et al.
Bone Marrow Transplantation|March 15, 2016
A novel reduced intensity conditioning regimen for patients with high-risk hematological malignancies undergoing allogeneic stem cell transplantationG S Hobbs, N Kaur, P Hilden, et al.
Pageof 18

Showing results (141-150 of 176) with videos related to

Sort By:
Pageof 18
Blood|November 24, 2001
The effect of pretransplant interferon therapy on the outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phaseS J Lee, J P Klein, C Anasetti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 15, 2008
High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients >65 years of ageC Hosing, R M Saliba, G-J Okoroji, et al.
Blood|December 1, 1996
Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantationD Przepiorka, C Ippoliti, I Khouri, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 1, 1997
Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patientsK van Besien, P Thall, M Korbling, et al.
Bone Marrow Transplantation|May 21, 2008
Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric populationJ E Levine, A J Barrett, M-J Zhang, et al.
Blood|December 1, 1995
CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantationS Giralt, J Hester, Y Huh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1997
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantationR H Collins, O Shpilberg, W R Drobyski, et al.
Bone Marrow Transplantation|October 12, 1999
Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantationD Przepiorka, I Khouri, C Ippoliti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 23, 1999
Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphomaD Przepiorka, K van Besien, I Khouri, et al.
Bone Marrow Transplantation|March 15, 2016
A novel reduced intensity conditioning regimen for patients with high-risk hematological malignancies undergoing allogeneic stem cell transplantationG S Hobbs, N Kaur, P Hilden, et al.
Pageof 18